[A14-15] Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Last updated 05.06.2014
Project no.:
A14-15
Commission:
Commission awarded on 07.05.2014 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment
| Project no. | Title | Status |
|---|---|---|
| A14-11 | Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) | Commission completed |
| A13-44 | Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |